TGFBR2 and neoplasm: Vaccination was found to be safe and well-tolerated, and to induce antigen-specific T cell responses, including T cell cytotoxicity against tumor cells presenting the TGFBR2 neoantigen, in several patients, with production of multiple cytokines and high levels of IFN-gamma detected in the peripheral blood of 87% of vaccinated patients [193].